Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction

Fig. 3

Methylation levels in Taiwanese colorectal carcinoma (CRC) patients. a Differentially methylated CpG heatmap of TMEM240 in 26 paired CRC patients. Methylation levels (average β values) at differentially methylated loci were identified using an Illumina Methylation 450K array-based assay. The highly differentially methylated sites cg15487867, cg16601494, cg16306898, and cg22497741 are array probes 6, 7, 8, and 9, respectively. The genomic positions of the QMSP amplicon are located in exon 1 (from + 171 to + 347) of the TMEM240 gene (array probes 7 and 8). b The box plot of TMEM240 methylation levels in tissues. c Representative figures of TMEM240 methylation levels determined by QMSP in 10 adjacent normal colon tissues, nine polyps of tubular adenoma, and 10 CRC tumors. Experiments were performed with three technical replicates. d The box plot of TMEM240 methylation levels in plasma. e Representative figures of the circulating methylated TMEM240 levels determined by QMSP in 10 healthy subjects and 10 CRC patients. *p ≤ 0.05, ***p ≤ 0.001. A t test was used to calculate group differences

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us